Zhangjiqin

Ph.D., 09/2007-06/2012, East China Normal University

B.S., 09/2003-06/2007, Tongji University

Professor, 09/2022-Present, East China Normal University (Institute of Biomedical Sciences, School of Life Sciences)

Associate Professor, 09/2016-08/2022, East China Normal University (Institute of Biomedical Sciences, School of Life Sciences)

Assistant Professor, 08/2012-08/2016, Group of Biotherapy, Shanghai Cancer Institute (Renji Hospital, Shanghai Jiaotong University School of Medicine)

Jiqin Zhang is a professor, a principal investigator at East China Normal University. He is engaged in the research of genome editing and immune cell therapy. In recent years, he has published more than 20 SCI papers in international academic journals such as Nature, Cancer Cell, Cell Research, Molecular Cancer and Nature Communications. As a leader, he has taken charge of two projects of National Natural Science Foundation of China and one project of Shanghai Natural Science Foundation. He also participated in several national and provincial scientific research projects. He first developed an innovative non-viral genome-specific targeted CAR-T cell technology, providing new strategies to break through the limitations of current CAR-T cell therapy.

1.Development of innovative CAR-T and other immune cell therapy technologies using novel genome editing tools

2.Identification of important proteins improving CAR-T cell therapy using new screening methods

1. Manager, 01/2018-12/2021, The function and mechanism of UHRF2 in promoting the development and progression of intestinal cancers by maintaining the stemness of cancer stem cells, the National Natural Science Foundation of China, No.81772622

2. Manager, 06/2018-05/2021, Study on exploring and optimizing methods for efficient incorporation of unnatural amino acids in vivo, Natural Science Foundation of Shanghai, No.18ZR1412300

3. Manager, 01/2014/-12/2016, Biological functions and mechanisms of a new EGFR isoform (EGFRvA) in the proliferation and metastases of ovarian cancer, the National Natural Science Foundation of China, No.81301819

4. The 2nd Manager, 01/2016-12/2018, Early clinical study of anti-GPC3 CAR-T cell therapy in hepatocellular cancer, Program of Shanghai Academic Research Leader, No.16XD1402600

1. Jiqin Zhang^#*, Yongxian Hu^#, Jiaxuan Yang^#, et al. Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL. Nature, 2022, 609(7926):369-374. (IF=69.504)

2. Yongxian Hu^#, Cheng Zu^#, Mingming Zhang^#, Guoqing Wei^#, Wei Li^#, Shan Fu, Ruimin Hong, Linghui Zhou, Wenjun Wu, Jiazhen Cui, Dongrui Wang, Bing Du, Mingyao Liu, Jiqin Zhang*, He Huang*. Safety and efficacy of CRISPR-based non-viral PD1 locus specifically integrated anti-CD19 CAR-T cells in patients with relapsed or refractory Non-Hodgkin's lymphoma: a first-in-human phase I study. eClinicalMedicine, 2023, 60:102010. (IF=17.033)

3. Jiqin Zhang*, Bing Du, Mingyao Liu*. Let's turn the CAR-T cells ON and OFF precisely. Cancer Cell, 2022, 40(11):1264-1266. (IF=38.585)

4. Xinyan Zhang^#, Shijie Liu^#, Yueqian Wang^#, Huiqiong Hu, Liang Li, Yibin Wu, Duo Cao, Yuankun Cai, Jiqin Zhang*, Xueli Zhang*. Interleukin-22 regulates the homeostasis of the intestinal epithelium during inflammation. Int J Mol Med, 2019, 43(4):1657-1668. (IF=5.314)

5. Jiqin Zhang^#, Fei Song^#, Xiaojing Zhao^#, et al. EGFR modulates monounsaturated fatty acid synthesis through phosphorylation of SCD1 in lung cancer. Mol Cancer, 2017, 16(1):127. (IF=41.444)

6. Yuanhui Jia^#, Ting Li^#, Xiaojie Huang, Xianghong Xu, Xinyao Zhou, Linyan Jia, Jingping Zhu,Dandan Xie, Kai Wang, Qian Zhou, Liping Jin, Jiqin Zhang*, Tao Duan*. Dysregulated DNA methyltransferase 3A upregulates IGFBP5 to suppress trophoblast cell migration and invasion in preeclampsia. Hypertension, 2017, 69(2):356-366. (IF=9.897)

7. Biao Wang^#, Jiqin Zhang^#, Fei Song, et al. EGFR regulates iron homeostasis to promote cancer growth through redistribution of transferrin receptor 1. Cancer Lett, 2016, 381(2):331-40. (IF=9.756)

8. Qian Zhao^#, Jiqin Zhang^#, Ruoyu Chen^#, et al. Dissecting the precise role of H3K9 methylation in crosstalk with DNA maintenance methylation in mammals. Nat Commun, 2016, 7:12464. (IF=17.694)

9. Fei Song, Min Zhou, Biao Wang, Bizhi Shi, Hua Jiang, Jiqin Zhang*, Zonghai Li*. Weak binding to E3 ubiquitin ligase c-Cbl increases EGFRvA protein stability. FEBS Lett, 2016, 590(9):1345-53. (IF=3.864)

10. Jiqin Zhang^#, Qinqin Gao^#, Pishun Li, et al. S phase-dependent interaction with DNMT1 dictates the role of UHRF1 but not UHRF2 in DNA methylation maintenance. Cell Res, 2011, 21(12):1723-39. (IF=46.297)

11. Wenhua Liang^#, Ruirong Yi^#, Weifang Wang^#, Yiwei Shi, Jiqin Zhang, et al. Enhancing the antitumor immunity of T cells by engineering the lipid-regulatory site of the TCR/CD3 complex. Cancer Immunol Res, 2023, 11(1):93-108. (IF=12.020)

12. Shuming Yin^#, Mei Zhang^#, Yang Liu^#, Xiaoyue Sun, Yuting Guan, Xi Chen, Lei Yang, Yanan Huo, Jing Yang, Xiaohui Zhang, Honghui Han, Jiqin Zhang, et al. Engineering of efficiency-enhanced Cas9 and base editors with improved gene therapy efficacies. Mol Ther, 2022, S1525-0016(22)00672-4. (IF=12.910)

13. Yuanhui Jia, Han Xie, Jiqin Zhang, et al. Induction of TGF-β receptor I expression in a DNA methylation-independent manner mediated by DNMT3A downregulation is involved in early-onset severe preeclampsia. FASEB J, 2020, 34(10):13224-13238. (IF=5.622)

14. Liang Li^#, Qiuhui Duan^#, Zhiyang Zeng^#, Jindong Zhao, Jiawei Lu, Jialiang Sun, Jiqin Zhang, et al. UHRF2 promotes intestinal tumorigenesis through stabilization of TCF4 mediated Wnt/β-catenin signaling. Int J Cancer, 2020, 147(8):2239-2252. (IF=7.316)

15. Lei Yang^#, Xiaohui Zhang^#, Liren Wang^#, Shuming Yin^#, Biyun Zhu, Ling Xie,  Qiuhui Duan, Huiqiong Hu, Rui Zheng, Yu Wei, Liangyue Peng, Honghui Han, Jiqin Zhang, et al. Increasing targeting scope of adenosine base editors in mouse and rat embryos through fusion of TadA deaminase with Cas9 variants. Protein Cell, 2018, 9(9):814-819. (IF=15.328)

16. Yanjiao Shao^#, Liren Wang^#, Nana Guo, Shengfei Wang, Lei Yang, Yajing Li, Mingsong Wang, Shuming Yin, Honghui Han, Li Zeng, Ludi Zhang, Qiurong Ding, Jiqin Zhang, et al. Cas9-nickase–mediated genome editing corrects hereditary tyrosinemia in rats.J Biol Chem, 2018, 293(18):6883-6892. (IF=5.486)

17. Xiuqi Wu, Bizhi Shi, Jiqin Zhang, et al. A fusion receptor as a safety switch, detection, and purification biomarker for adoptive transferred T cells.  Mol Ther, 2017, 25(10):2270-2279. (IF=12.91)

18. Wen Xu, Yanyu Bi, Juan Kong, Jiqin Zhang, et al. Combination of an anti-EGFRvIII antibody CH12 with Rapamycin synergistically inhibits the growth of EGFRvIII+PTEN–glioblastoma in vivo. Oncotarget, 2016, 26;7(17):24752-65.

19. Wen Xu^#, Yanyu Bi^#, Jiqin Zhang, et al. Synergistic antitumor efficacy against the EGFRvIII+HER2+ breast cancers by combining trastuzumab with anti-EGFRvIII antibody CH12. Oncotarget, 2015, 6(36):38840-53.

20. Hua Jiang^#, Qiongna Dong^#, Xiaoying Luo, Bizhi Shi, Huamao Wang, Huiping Gao, Juan Kong, Jiqin Zhang, et al. The monoclonal antibody CH12 augments 5-fluorouracil-induced growth suppression of hepatocellular carcinoma xenografts expressing epidermal growth factor receptor variant III. Cancer Lett, 2014, 342(1):113-20. (IF=9.756)

21. Min Zhou^#, Hai Wang^#, Keke Zhou^#, Xiaoying Luo#, Xiaorong Pan#, Bizhi Shi, Hua Jiang, Jiqin Zhang, et al. A novel EGFR isoform confers increased invasiveness to cancer cells. Cancer Res, 2013, 73(23):7056-67. (IF=13.312)

22. Xiaoli Liu^#, Qinqin Gao^#, Pishun Li^#, Qian Zhao, Jiqin Zhang, et al. UHRF1 targets DNMT1 for DNA methylation through cooperative binding of hemi-methylated DNA and methylated H3K9. Nat Commun, 2013, 4:1563. (IF=17.694)

23. Jing He, Lan Kang, Tong Wu, Jiqin Zhang, et al. An elaborate regulation of mammalian target of rapamycin activity is required for somatic cell reprogramming induced by defined transcription factors. Stem Cells Dev, 2012, 21(14):2630-41. (IF=4.39)

24. Yixuan Wang^#, Chenguang Zheng^#, Yonghua Jiang, Jiqin Zhang, et al. Genetic correction of β-thalassemia patient-specific iPS cells and its use in improving hemoglobin production in irradiated SCID mice. Cell Res, 2012, 22(4):637-48. (IF=46.297)

1. National Natural Science Foundation of China for Excellent Young Scholar (2023)

2. ECNU Zijiang Excellent Young Scholar (2022)

3. One of the China’s Top 10 Hematological Advances in 2022

4. One of the China’s Important Medical Advances in 2022